Search Within

Prakirthi Yerram

Formats
  1. Journal Article (5)
  2. Meeting Abstract (4)
Groups
  1. Clinical Pharmacy Specialists (7)
  2. Biostatistics Service (2)
  3. Epidemiology and Biostatistics (2)
  4. Population Sciences Research Program (2)
  5. Department of Pathology and Laboratory Medicine (1)
  6. Tow Center for Developmental Oncology (TCDO) (1)
People
  1. Lisa Modelevsky (7)
  2. Samantha Reiss (7)
  3. Christian Grommes (4)
  4. Anne Reiner (2)
  5. Igor Gavrilovic (2)
  6. Katherine Panageas (2)

More People

Years
  1. 2023 (1)
  2. 2021 (1)
  3. 2019 (4)
  4. 2018 (1)
  5. 2017 (2)
Publications
  1. Neuro-Oncology (3)
  2. Annals of Lymphoma (1)
  3. Blood (1)
  4. Journal for ImmunoTherapy of Cancer (1)
  5. Journal of Neuro-Oncology (1)
  6. Journal of Oncology Pharmacy Practice (1)

More Publications

Publishers
  1. Oxford University Press (3)
  2. AME Publishing Company (1)
  3. American Society of Hematology (1)
  4. Biomed Central Ltd (1)
  5. Elsevier Inc. (1)
  6. Sage Publications Ltd. (1)

More Publishers

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort
    Journal Article

    Yerram, P.; Reiss, S. N.; Modelevsky, L.; Schaff, L.; Reiner, A. S.; Panageas, K. S.; Grommes, C.
    Annals of Lymphoma (2023)

    Fulltext@MSK | Save
  • Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City
    Journal Article

    Yerram, P.; Thackray, J.; Modelevsky, L. R.; Land, J. D.; Reiss, S. N.; Spatz, K. H.; Levoir, A. C.; Pak, T. K.; Dao, P. H.; Buege, M. J.; more...
    Journal of Oncology Pharmacy Practice (2021)

    Fulltext@MSK | Save
  • Increased number of high dose methotrexate cycles and the addition of rituximab is associated with better outcomes in a large primary CNSL cohort
    Meeting Abstract

    Yerram, P.; Reiss, S. N.; Modelevsky, L.; Schaff, L.; Reiner, A.; Panageas, K.; Grommes, C.
    Blood (2019)

    Fulltext@MSK | Save
  • Rituximab, methotrexate, BCNU, etoposide, and prednisone (RMBVP) for the treatment of relapsed/recurrent primary central nervous system lymphoma: A retrospective single center study
    Meeting Abstract

    Reiss, S.; Yerram, P.; Modelevsky, L.; Grommes, C.
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • Germline predictors of hematologic toxicity in patients with glioma treated with chemotherapy
    Meeting Abstract

    Sener, U.; Bhatia, A.; DeAngelis, L.; Mandelker, D.; Yerram, P.
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas
    Journal Article

    Yerram, P.; Reiss, S. N.; Modelevsky, L.; Gavrilovic, I. T.; Kaley, T.
    Journal of Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • Immunotherapy in gliomas
    Journal Article

    Weant, M. P.; Mejías-De Jesús, C.; Yerram, P.
    Seminars in Oncology Nursing (2018)

    Fulltext@MSK | Save
  • Toxicity of single agent carmustine versus carmustine plus bevacizumab in patients with recurrent or progressive high grade gliomas
    Meeting Abstract

    Yerram, P.; Reiss, S.; Modelevsky, L.; Gavrilovic, I.; Kaley, T.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
    Journal Article

    Reiss, S. N.; Yerram, P.; Modelevsky, L.; Grommes, C.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save